§ 866.3950. In vitro human immunodeficiency virus (HIV) drug resistance genotype assay.
110 words·~1 min read·
/us/cfr/t21/s§ 866.3950·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
(a)Identification. The in vitro HIV drug resistance genotype assay is a device that consists of nucleic acid reagent primers and probes together with software for predicting drug resistance/susceptibility based on results obtained with these primers and probes. It is intended for use in detecting HIV genomic mutations that confer resistance to specific antiretroviral drugs, as an aid in monitoring and treating HIV infection.
(b)Classification. Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: In Vitro HIV Drug Resistance Genotype Assay.” See § 866.1(e) for the availability of this guidance document. [72 FR 44382, Aug. 8, 2007]
Connections1 cite this
Cited by 1 section
register
Citation graph
cites case law
§ 866.3950
In vitro human immunodeficiency virus (HIV) drug resistance genotype assay.
Fed. Reg.×1
Cites 0Cited by 1 across 1 source